FDA Brief

Warning letters Drugs

FDA warning letter to

US Chem Labs

High riskIssued Feb 7, 2024Posted Feb 13, 2024Center for Drug Evaluation and Research | CDER

FDA warned US Chem Labs that it sells unapproved and misbranded Semaglutide, Tirzepatide, and Thymalin drugs online.

What happened

FDA reviewed www.uschemlabs.com in October 2023 and found the website offering Semaglutide, Tirzepatide, and Thymalin for sale in the United States. The site made claims that the products treat diabetes, support weight loss, or affect the immune and endocrine systems, even though labeling called them "research chemicals only" and "not for human consumption." FDA concluded the products are unapproved new drugs and misbranded, and said it was particularly concerned that Thymalin was marketed for use in children.

What FDA found

  1. The products are unapproved new drugs sold without an FDA-approved application.

    sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. The product labeling lacks adequate directions for use, so the drugs are misbranded.

    section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1)
  3. Website claims show the products are intended as drugs for human use despite "research chemicals only" statements.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  4. Thymalin is marketed for use in children even though FDA has not evaluated it for safety, effectiveness, or quality.

What FDA wants

FDA asks US Chem Labs to notify it in writing within 15 working days of the steps taken to address the violations, including explanations and supporting documents. If corrective actions cannot be completed in that time, the company must state why and when it will finish.

Who should pay attention

  • online sellers of research chemicals and peptides
  • clinics or compounding pharmacies considering unapproved semaglutide or tirzepatide
  • consumers buying weight-loss or immune products from websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk